Informatie over MSc Medical Pharmaceutical Sciences: Science, Business and Policy
Hieronder staan het programma en de vakomschrijvingen van MSc Medical Pharmaceutical Sciences: Science, Business and Policy Klik op de naam van een vak in een schema om naar de omschrijving te gaan.
» General Outline | |||||||
Periode | Type | Code | Naam | Taal | ECTS | Uren | |
---|---|---|---|---|---|---|---|
hele jaar | verplicht | WMMP14C001 | Colloquium | Engels | 5 | ||
verplicht | MLELMPS5 | Electives MPS-SBP | Engels | 10 | |||
verplicht | MLMODMPS5 | Master Modules MPS-SBP | Engels | 25 | |||
verplicht | WMMP14RP2 | Research Project 2 | Engels | 40 | |||
semester I b | verplicht | WNBIBEBS08 | Stagetraject bedrijf en beleid | Engels en Nederlands | 40 | ||
Opmerkingen | See below for Master courses and Electives | ||||||
» Master Courses | |||||||
Periode | Type | Code | Naam | Taal | ECTS | Uren | |
semester I a | verplicht | WMMP18001 | Drug Development: from Design to Evaluation | Engels | 5 | ||
verplicht | WNBIBEB08A | Introduction Science and Business | Engels | 10 | |||
verplicht | WNBIBEB08B | Introduction Science and Policy | Engels | 10 | 40 | ||
» Electives (10 ECTS) | |||||||
Periode | Type | Code | Naam | Taal | ECTS | Uren | |
hele jaar | keuze | WLFM1007 | Advanced Pharmacoepidemiology | Engels en Nederlands | |||
keuze | MLAA01 | Animal and Human Experimentation | Engels | 5 | |||
keuze | WMFA19006 | Inleiding Farmaceutische Industrie | Nederlands | ||||
keuze | WMFA19004 | Niet-steriele toedieningsvormen | Nederlands | 5 | |||
keuze | WLFM1041 | Probleemoplossen in de producttechnologie | Engels en Nederlands | 6 | |||
semester I | keuze | WMMP14001 | Advanced Topics in Pharmacoepidemiology (19/20) | Engels | 5 | ||
keuze | WMMP15001 | Microbiological Safety | Engels | 1 | 16 | ||
semester I a | keuze | MLMPS04 | Advanced pharmacokinetics | Engels | 5 | ||
keuze | MLBCNB07 | Behavioural Pharmacology | Engels | 5 | |||
keuze | WLFM1114 | Farmaceutische biologie practicum | Engels en Nederlands | 5 | |||
keuze | WMBM17001 | From Big Data to Personalised Medicine | Engels | 5 | |||
keuze | MLMPS06 | Molecular Toxicology | Engels | 5 | |||
keuze | WMMP18004 | Pharmaceutical Design and Engineering | Engels | 5 | |||
keuze | WLFM1038 | Pharmacoeconomics | Engels en Nederlands | 5 | |||
keuze | WLFM1039 | Pharmaco-epidemiology in Practice | Engels en Nederlands | 5 | |||
keuze | WMEC13007 | Research Methods in SEC | Engels | 5 | |||
keuze | WMBM12001 | Scientific writing | Engels | 5 | |||
keuze | MLBB010 | Tools and approaches of systems biology | Engels | 5 | |||
semester I b | keuze | WMFA13002 | Farmaceutische biotechnologie | Engels en Nederlands | 5 | ||
keuze | WMFA14008 | Klinische Toxicologie | Engels | 5 | |||
keuze | WMBM18001 | Neurobiology of Psychiatric Disorders | Engels | 5 | |||
keuze | WMMP13001 | Pharmacoepidemiology | Engels | 5 | |||
keuze | WMLS17003 | Programming C++ for Biologists | Engels | 5 | |||
keuze | MLAA03 | Radioisotopes in Experimental Biology | Engels | 5 | |||
keuze | WMMP17001 | Reproductive Toxicology and Epidemiology | Engels | 5 | |||
semester II | keuze | WMLS09002 | Orientation on International Careers | Engels | 5 | ||
semester II a | keuze | WLB07045 | Biotechnologie | Engels en Nederlands | 10 | ||
keuze | WMFA15001 | Nanomedicine and nanosafety | Engels | 5 | |||
keuze | WMFA16003 | Pharmacology of Chronic Diseases and Ageing | Engels en Nederlands | 5 | |||
keuze | MLMPS03 | Pharmacovigilance | Engels | 5 | |||
keuze | WMFA14005 | Quantitative Bioanalysis | Engels | 5 | |||
semester II b | keuze | MLBI0901 | Advanced Imaging techniques | Engels | 5 | ||
keuze | WMLS13004 | Advanced Light Microscopy | Engels | 5 | |||
keuze | WMLS19002 | Advanced Statistics | Engels | 6 | |||
keuze | WLFM1113 | Medicinale Natuurstoffen | Engels en Nederlands | 10 |
1 | Advanced Imaging techniques | MLBI0901 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
2 | Advanced Light Microscopy | WMLS13004 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
3 | Advanced Pharmacoepidemiology | WLFM1007 | |||||||||||||||||||||||||||
Student werkt individueel (of eventueel in een klein groepje) aan een methodologisch vraagstuk en wordt hierbij individueel begeleid. | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
4 | Advanced pharmacokinetics | MLMPS04 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
5 | Advanced Statistics | WMLS19002 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
6 | Advanced Topics in Pharmacoepidemiology (19/20) | WMMP14001 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
7 | Animal and Human Experimentation | MLAA01 | |||||||||||||||||||||||||||
This course is in transition to a completely new e-learning format in 2020. Please be prepared for possible change during the academic year. The learning objectives, content and judgement will be very similar, but the format is changed to learning via videos, quizzes, and assignments. Enrolling in this course is only finalized once you will have completed following your first instruction in NESTOR. Thereafter, selected course participants will work within a google classroom environment, where more detailed information will be provided. The aim of the course is to prepare students starting a master research project in which they participate in animal or human experimentation, with respect to methodological, practical and ethical aspects. At the end the students are prepared to carry out the masterproject, under supervision of and guided by the CCD or METC permit holder. The course has a blended classroom format with a limited contact hours. The students complete an online portfolio after practical instructions in their master project, and conduct the theoretical part as a homework assignment. They will also participate in a tour through the animal/human facility to learn about practical procedures while performing their study and the people involved, and attend a contact hour with an interactive lecture when topics can be discussed. The theoretical part consists of 6 modules containing information on (1) Ethics and researcher integrity in animal and human experimentation, (2) Rules & Regulations in animal and human experimentation, (3) Research question, experimental and statistical design, (4) Choice of experimental model and subjects, (5) Animal experimentation in practice, and (6) Human experimentation in practice. By in-depth reading of scientific papers, looking up content on the internet and by self-reflection, students will learn about scientific, practical and societal aspects of working with animals and/or humans during their masterproject. | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
8 | Behavioural Pharmacology | MLBCNB07 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
9 | Biotechnologie | WLB07045 | |||||||||||||||||||||||||||
The course is designed for students in their 3rd or 4th year, and is based on an integrated approach, with several practical examples illustrating the whole proces of development from an idea to a product. The course consists of two parts, a Food section and a Pharma section (total of 46 lectures). Within these sections there will be a number of lectures in applicational aspects, partially by lecturers from companies. Obligatory parts of the course are an excursion week, in which 5 to 7 Dutch biotechnology companies in the Food and Pharma sector will be visited, as well as a debate on a socially relevant aspect of biotechnology with experts in the field. | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
10 | Colloquium | WMMP14C001 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
11 | Drug Development: from Design to Evaluation | WMMP18001 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
12 | Electives MPS-SBP | MLELMPS5 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
13 | Farmaceutische biologie practicum | WLFM1114 | |||||||||||||||||||||||||||
Het keuzevak Farmaceutische Biologie zal gericht zijn op het soort onderzoek dat binnen de afdeling Farmaceutische Biologie door promovendi wordt gedaan. Deelnemers krijgen voor de duur van het practicum een onderzoeksproject op het gebied van isoleren/produceren en identificeren van farmaceutische stoffen. Er kan gebruik gemaakt worden van verschillende analyse methoden, zoals GC, GCMS, HPLC, TLC en MS. Door gebruik te maken van genetisch gemodificeerde organismen wordt getracht om op synthetische wijze farmaceutische stoffen te produceren in celsystemen. Naast het identificeren en analyseren gaan we tevens bepalen wat de biologische effecten zijn van de geïsoleerde stoffen op cellijnen middels celbiologische assays. De technieken die aan de orde komen zijn eiwitisolatie, weefselkweek, microscopie, cytotoxiciteit assays, immunodetectie en western blot analysis. Binnen dit practicum wordt van de deelnemers een grote mate van zelfstandigheid en inventiviteit verwacht. | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
14 | Farmaceutische biotechnologie | WMFA13002 | |||||||||||||||||||||||||||
Kennismaken met methoden voor moleculair biologisch en biotechnologisch onderzoek naar: - De synthese en transformatie van farmaceutisch relevante verbindingen m.b.v. plantencel/weefselcultures, bacteriën en geïsoleerde enzymen. - Het ontwikkelen van cytokines (eiwitten) en enzymen met veranderde eigenschappen door protein engineering/directed evolution. - De secretie van biopharmaceuticals door bacteriën. - Nieuwe mogelijkheden voor gentherapie. Technieken: DNA-isolatie, Polymerase-kettingreactie (PCR), DNA-clonering, eiwit-expressie, eiwitisolatie, enzymassays, analyse van stoffen met HPLC en NMR, kweektechnieken voor bacteriën, humane cellen en/of plantencellen. | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
15 | From Big Data to Personalised Medicine | WMBM17001 | |||||||||||||||||||||||||||
At the end of the course, the student is able to: 1) - reproduce the basic principles and usage of state-of-the-art genomics, transcriptomics and epigenetic research techniques 2) - argue why large biobanks and public data can make an impact on biomedical research 3) - outline various ways in which genetic variation, epigenetics and protein levels can affect disease outcome 4) - articulate what personalized medicine is 5) - apply a research question in the experimental set-up of a clinically relevant genomics project 6) - generate transcriptomics data in the context of a clinically relevant genomics project 7) - utilize data of various large (epigenetic) consortia (epigenome roadmap, ENCODE, Blueprint, GTex, etc) 8) - integrate transcriptomics data and with other genomics data 9) - report the outcomes of a genomics project in a short research manuscript | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
16 | Inleiding Farmaceutische Industrie | WMFA19006 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
17 | Introduction Science and Business | WNBIBEB08A | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
18 | Introduction Science and Policy | WNBIBEB08B | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
19 | Klinische Toxicologie | WMFA14008 | |||||||||||||||||||||||||||
In deze cursus komen de volgende onderwerpen aan bod:
| |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
20 | Master Modules MPS-SBP | MLMODMPS5 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
21 | Medicinale Natuurstoffen | WLFM1113 | |||||||||||||||||||||||||||
De cursus is gericht op geneesmiddelen die uit de natuur geïsoleerd kunen worden. Deelnemers krijgen voor de duur van de cursus een onderzoeksproject. Hierbij worden eerst uit plantaardig materiaal natuurstoffen (b.v. alkaloiden, terpenoiden, flavonoiden) geïsoleerd volgens bestaande of nieuw te ontwikkelen voorschriften. De geïsoleerde verbindingen worden geïdentificeerd en geanalyseerd m.b.v. TLC, IR, GC, GC-MS, HPLC, LC-MS en NMR (H1,C13). Tevens wordt de relevantie van deze analyses voor de werking als geneesmiddel onderwezen. De voortgang van de projecten wordt wekelijks met behulp van Powerpoint gepresenteerd. Binnen dit practicum wordt van de deelnemers een grote mate van zelfstandigheid en inventiviteit verwacht. | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
22 | Microbiological Safety | WMMP15001 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
23 | Molecular Toxicology | MLMPS06 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
24 | Nanomedicine and nanosafety | WMFA15001 | |||||||||||||||||||||||||||
This course covers the following topics: • nanomedicine for drug delivery and drug targeting • nanomedicine applications other than drug delivery and drug targeting (organ-on-a-chip devices, tissue regeneration, stem cell differentiation and assisted surgery) • overview of main classes of nanomedicines, such as lipid based drug carriers, polymer based drug carriers, inorganic nanoparticles, antibodies and immunoconjugates, biomimetic materials, viral based nanocarriers • drug carriers and targeted drugs currently on the market and in clinical trials • challenges in nanomaterial design for successful targeting and barriers to drug delivery; • methods to characterize nano-sized drug carriers after synthesis and once applied in biological environments (size, charge, stability in biological fluids such as blood); • behavior of nano-sized materials at cellular and and organism level (uptake, distribution, final fate, eventual effects on cellular functions); • potential risks and safety concerns for nanomedicines and nano-sized materials not intended to be in contact with humans and living organisms (other nanotechnologies). | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
25 | Neurobiology of Psychiatric Disorders | WMBM18001 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
26 | Niet-steriele toedieningsvormen | WMFA19004 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
27 | Orientation on International Careers | WMLS09002 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
28 | Pharmaceutical Design and Engineering | WMMP18004 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
29 | Pharmacoeconomics | WLFM1038 | |||||||||||||||||||||||||||
Colleges over farmaco-economie. Tijdens de werkcolleges worden farmaco-economische opdrachten uitgewerkt en wordt er geoefend met farmaco-economisch onderzoek. Aldus omvat de inhoud: - Een introductie in de theoretische aspecten van de farmaco-economie en de economie van de gezondheidszorg; - Bediscussiëring van door de docent aangereikte case-studies - Omschrijving en berekening van farmaco-economische grootheden (gezondheidswinst, discontering en kosteneffectiviteitsratio) - Statistische en mathematische aspecten bij modellen voor de kosteneffectiviteit - Toepassing van de Nederlandse richtlijnen voor farmaco-economisch onderzoek van het College voor Zorgverzekeraars op concrete recente cases (vergoedingsdossiers) - Werken met farmaco-economische software DATA (en/of EXCEL) | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
30 | Pharmacoepidemiology | WMMP13001 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
31 | Pharmaco-epidemiology in Practice | WLFM1039 | |||||||||||||||||||||||||||
Colleges over Farmaco-epidemiologie worden gegeven ter verdieping op de basiscursus Farmaco-epidemiologie. Studenten werken epidemiologische opdrachten uit. Tevens wordt er een computerpracticum gegeven en hebben studenten 2 keer per week een contactuur met docenten. | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
32 | Pharmacology of Chronic Diseases and Ageing | WMFA16003 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
33 | Pharmacovigilance | MLMPS03 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
34 | Probleemoplossen in de producttechnologie | WLFM1041 | |||||||||||||||||||||||||||
Tijdens de cursus werken de studenten in groepjes aan problemen en ontwikkelingsprojecten welke afkomstig zijn uit de praktijk. Uitgaande van het door de studenten zelf opgestelde werkplan moet onderzoek worden uitgevoerd waarmee de aangereikte problemen kunnen worden opgelost of het gevraagde ontwikkelingsdoel bereikt. | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
35 | Programming C++ for Biologists | WMLS17003 | |||||||||||||||||||||||||||
This course, which is specifically designed for biology students, teaches the participants how to develop software in the programming language C++. Emphasis is given to the implementation of biological models, using individual-based simulations and various numerical methods for dynamical systems analysis. Students are able to tailor the contents of the course to their own level of proficiency. For students with no prior programming experience, the course offers an introduction to the essentials of the C++ programming language, including: • Procedural programming: data types, operators, program flow and functions • The Standard Template Library • Data input, generation of output including statistics like mean and standard deviation • Numerical simulation techniques for biological models More experienced programmers (including those who followed the BSc level course WBLS16002) can instead focus on advanced topics, such as: • Program design, algorithms and debugging • Pointers and memory allocation • Object-oriented programming • Pseudo-random numbers and stochastic simulations The course consists of two parts: during the first three weeks (5 ECTS), students extend their programming skills by learning a new element of the programming language each day, and practise its application in programming exercises. The final three weeks of the course (5 ECTS) are devoted to a programming project. Here, students work on a biological research question of their choice and design and implement a simulation algorithm from scratch. They also learn how to systematically collect simulation data, and to present their results in an oral presentation, with associated annotated program code and documentation. Students may choose to omit the final project and receive a grade for a 5 ECTS course (MLAA05) after completing the first half of the program, or may work independently on their programming project at a suitable later time. The course is also available as a selfstudy course. | |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
36 | Quantitative Bioanalysis | WMFA14005 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
37 | Radioisotopes in Experimental Biology | MLAA03 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
38 | Reproductive Toxicology and Epidemiology | WMMP17001 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
39 | Research Methods in SEC | WMEC13007 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
40 | Research Project 2 | WMMP14RP2 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
41 | Scientific writing | WMBM12001 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
42 | Stagetraject bedrijf en beleid | WNBIBEBS08 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||
43 | Tools and approaches of systems biology | MLBB010 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
terug naar boven | |||||||||||||||||||||||||||||